Elena Trevisi

Dr. Elena Trevisi


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2018 in Annals of Oncology
Verified
Journal Article
Closed access
LML. Marandino
L. Marandino
ASA. La Salvia
A. La Salvia
CSC. Sonetto
C. Sonetto
ELE. De Luca
E. De Luca
DPD. Pignataro
D. Pignataro
Massimo Di MaioMassimo Di Maio
Massimo Di Maio
Quality of life (QoL) is a relevant end point and a topic of growing interest by both scientific community and regulatory authorities. Our aim was to review QoL prevalence as an end point in cancer phase III trials published in major journals and to evaluate QoL reporting deficiencies in terms of under-reporting and delay of publication. All issues published between 2012 and 2016 by 11 major journals were hand-searched for primary publications of phase III trials in adult patients with solid tumors. Information about end points was derived from paper and study protocol, when available. Secondary QoL publications were searched in PubMed. In total, 446 publications were eligible. In 210 (47.1%), QoL was not included among end points. QoL was not an end point in 40.1% of trials in the advanced/metastatic setting, 39.7% of profit trials and 53.6% of non-profit trials. Out of 231 primary publications of trials with QoL as secondary or exploratory end point, QoL results were available in 143 (61.9%). QoL results were absent in 37.6% of publications in the advanced/metastatic setting, in 37.1% of profit trials and 39.3% of non-profit trials. Proportion of trials not including QoL as end point or with missing QoL results was relevant in all tumor types and for all treatment types. Overall, 70 secondary QoL publications were found: for trials without QoL results in the primary publication, probability of secondary publication was 12.5%, 30.9% and 40.3% at 1, 2 and 3 years, respectively. Proportion of trials not reporting QoL results was similar in trials with positive results (36.5%) and with negative results (39.4%), but the probability of secondary publication was higher in positive trials. QoL is not included among end points in a relevant proportion of recently published phase III trials in solid tumors. In addition, QoL results are subject to significant under-reporting and delay in publication.

25 July 2020 in Medical Oncology
Verified
Journal Article
Open access
PDF file
ETElena Trevisi
Elena Trevisi
ASAnna La Salvia
Anna La Salvia
LDLorenzo Daniele
Lorenzo Daniele
MBMaria Pia Brizzi
Maria Pia Brizzi
GRGiovanni De Rosa
Giovanni De Rosa
MMMassimo Di Maio
Massimo Di Maio
Breast carcinoma with neuroendocrine differentiation, also known as neuroendocrine breast carcinoma (NEBC), includes a heterogeneous group of rare tumors, which account for 2–5% of all invasive breast carcinomas. Because of their low incidence, most of the current limited knowledge of these tumors derives from anecdotal case reports or small retrospective series. The diagnosis of NEBC is based on the presence of morphological features similar to gastrointestinal and lung NETs and neuroendocrine markers. NEBCs are usually hormone receptors positive and HER2 negative, but despite this luminal phenotype, most recent studies suggested that NEBC could be associated with worse prognosis compared to invasive breast cancer without neuroendocrine differentiation. Due to its rarity and lack of randomized data, there is little evidence to guide the choice of treatment, so NEBC is currently treated as any invasive breast carcinoma not-otherwise specified. Recently, attempts to molecularly characterize NEBC have been made, in order to provide new targets for a more personalized treatment of this uncommon entity.

1 January 2020 in Lung Cancer
Verified
Journal Article
Closed access
MRMaria Lucia Reale
Maria Lucia Reale
ELEmmanuele De Luca
Emmanuele De Luca
PLPasquale Lombardi
Pasquale Lombardi
LMLaura Marandino
Laura Marandino
CZClizia Zichi
Clizia Zichi
Massimo Di MaioMassimo Di Maio
Massimo Di Maio

1 February 2020 in Critical Reviews in Oncology/Hematology
Verified
Journal Article
Closed access
PLPasquale Lombardi
Pasquale Lombardi
LMLaura Marandino
Laura Marandino
ELEmmanuele De Luca
Emmanuele De Luca
CZClizia Zichi
Clizia Zichi
MRMaria Lucia Reale
Maria Lucia Reale
Massimo Di MaioMassimo Di Maio
Massimo Di Maio

3 May 2024 in European Urology Oncology
Verified
Journal Article
Open access
MPMartino Pedrani
Martino Pedrani
GSGiuseppe Salfi
Giuseppe Salfi
Sara MerlerSara Merler
Sara Merler
ITIrene Testi
Irene Testi
MCMassimiliano Cani
Massimiliano Cani
RPRicardo Pereira-Mestre
Ricardo Pereira-Mestre
Mutations in the speckle-type POZ (SPOP) gene are frequently identified in prostate cancer (PC); yet, prognostic implications for affected patients remain unclear. Limited consensus exists regarding tailored treatments for SPOP-mutant (SPOPmut) PC. To elucidate the prognostic and predictive significance of SPOP mutations across distinct PC stages and treatments. A systematic literature search of PubMed, Embase, and Scopus was conducted up to January 29, 2024. The meta-analysis included studies comparing survival outcomes between SPOPmut and SPOP wild-type (SPOPwt) PC. From 669 records, 26 studies (including five abstracts) were analyzed. A meta-analysis of metastasis-free survival in localized (hazard ratio [HR]: 0.72, 95% confidence interval [CI]: 0.59-0.88; p < 0.01) and overall survival (OS) in metastatic PC (HR: 0.64, 95% CI: 0.53-0.76; p < 0.01) showed a favorable prognosis for patients with SPOPmut PC. In metastatic settings, SPOP mutations correlated with improved progression-free survival (PFS) and OS in patients undergoing androgen deprivation therapy ± androgen receptor signaling inhibitor (HR: 0.51, 95% CI: 0.35-0.76, p < 0.01, and HR: 0.60, 95% CI:0.46-0.79, p < 0.01, respectively). In metastatic castration-resistant PC, only abiraterone provided improved PFS and OS to patients with SPOP mutations compared with patients with SPOPwt, but data were limited. SPOP mutations did not correlate with improved PFS (p = 0.80) or OS (p = 0.27) for docetaxel. Patients with SPOPmut PC seem to exhibit superior oncological outcomes compared with patients with SPOPwt. Tailored risk stratification and treatment approaches should be explored in such patients. Speckle-type POZ (SPOP) mutations could be a favorable prognostic factor in patients with prostate cancer (PC) and may also predict better progression-free and overall survival than treatment with hormonal agents. Therefore, less intensified treatments omitting chemotherapy for patients with SPOP-mutant PC should be explored in clinical trials.

1 October 2019 in Clinical Genitourinary Cancer
Verified
Journal Article
Closed access
LMLaura Marandino
Laura Marandino
ELEmmanuele De Luca
Emmanuele De Luca
CZClizia Zichi
Clizia Zichi
PLPasquale Lombardi
Pasquale Lombardi
MRMaria Lucia Reale
Maria Lucia Reale
Massimo Di MaioMassimo Di Maio
Massimo Di Maio